# Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult

> **NCT06099613** · PHASE1,PHASE2 · COMPLETED · sponsor: **EyeGene Inc.** · enrollment: 40 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** EG-COVII

## Key facts

- **NCT ID:** NCT06099613
- **Lead sponsor:** EyeGene Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-30
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-02-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099613, "Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06099613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*